Natera, Inc. NTRA
We take great care to ensure that the data presented and summarized in this overview for Natera, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NTRA
View all-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.97 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY6.77MShares$1.16 Billion0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY4.63MShares$796 Million0.05% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.56MShares$784 Million2.91% of portfolio
-
Fred Alger Management, LLC New York, NY4.01MShares$690 Million2.57% of portfolio
-
Stanley Druckenmiller Duquesne Family Office LLC | New York, Ny3.57MShares$613 Million15.34% of portfolio
-
State Street Corp Boston, MA3.49MShares$601 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.87MShares$494 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA2.8MShares$481 Million0.06% of portfolio
-
Rtw Investments, LP New York, NY2.59MShares$446 Million5.25% of portfolio
Latest Institutional Activity in NTRA
Top Purchases
Top Sells
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Insider Transactions at NTRA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
25,931
-9.57%
|
$4,356,408
$168.45 P/Share
|
Jan 22
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
78,553
-11.35%
|
$13,196,904
$168.46 P/Share
|
Jan 22
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,039
-4.6%
|
$3,702,552
$168.45 P/Share
|
Jan 22
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
971
-0.18%
|
$163,128
$168.43 P/Share
|
Jan 21
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+0.84%
|
-
|
Jan 21
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,775
+0.51%
|
-
|
Jan 21
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.27%
|
-
|
Jan 21
2025
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
144
+0.05%
|
-
|
Jan 20
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,522
+1.12%
|
-
|
Jan 20
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,386
+0.97%
|
-
|
Jan 20
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+0.36%
|
-
|
Jan 20
2025
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
191
+0.07%
|
-
|
Jan 16
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,730
+23.01%
|
-
|
Jan 16
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,348
+20.71%
|
-
|
Jan 16
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
101,812
+22.99%
|
-
|
Jan 16
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
54,175
+18.47%
|
-
|
Jan 16
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
54,316
+10.54%
|
-
|
Jan 16
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
48,548
+9.43%
|
-
|
Jan 16
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,832
+9.44%
|
-
|
Jan 16
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,696
+6.03%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 643K shares |
---|---|
Exercise of conversion of derivative security | 1.54M shares |
Bona fide gift | 111K shares |
Open market or private sale | 1.47M shares |
---|---|
Bona fide gift | 123K shares |